| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Germany | 85 | 2021 | 9196 | 4.40 | Why? |
| Dementia | 19 | 2019 | 1861 | 4.25 | Why? |
| Hypoglycemic Agents | 16 | 2021 | 2165 | 3.56 | Why? |
| General Practice | 19 | 2019 | 718 | 3.48 | Why? |
| Medication Adherence | 11 | 2019 | 1270 | 3.07 | Why? |
| Drug Prescriptions | 16 | 2020 | 1062 | 3.02 | Why? |
| Practice Patterns, Physicians' | 22 | 2019 | 4927 | 2.86 | Why? |
| Diabetes Mellitus, Type 2 | 20 | 2021 | 6166 | 2.63 | Why? |
| Anticonvulsants | 6 | 2019 | 634 | 2.21 | Why? |
| General Practitioners | 9 | 2019 | 568 | 2.15 | Why? |
| Norepinephrine | 3 | 2019 | 152 | 2.15 | Why? |
| Adjustment Disorders | 4 | 2017 | 66 | 1.93 | Why? |
| Glycated Hemoglobin A | 8 | 2018 | 1316 | 1.80 | Why? |
| Insulin | 6 | 2021 | 1316 | 1.72 | Why? |
| Antihypertensive Agents | 7 | 2020 | 1962 | 1.72 | Why? |
| Polypharmacy | 3 | 2018 | 347 | 1.71 | Why? |
| Dipeptidyl-Peptidase IV Inhibitors | 5 | 2021 | 436 | 1.68 | Why? |
| Drug Utilization | 9 | 2017 | 619 | 1.63 | Why? |
| Epilepsy | 7 | 2021 | 1401 | 1.46 | Why? |
| Neuropsychiatry | 2 | 2017 | 81 | 1.29 | Why? |
| Databases, Factual | 23 | 2021 | 6248 | 1.27 | Why? |
| Pharmacies | 2 | 2021 | 356 | 1.22 | Why? |
| Pharmacy | 2 | 2021 | 326 | 1.22 | Why? |
| Depression | 11 | 2021 | 14116 | 1.18 | Why? |
| Antipsychotic Agents | 4 | 2018 | 887 | 1.17 | Why? |
| Breast Neoplasms | 8 | 2018 | 3633 | 1.10 | Why? |
| Benzodiazepines | 5 | 2018 | 163 | 1.09 | Why? |
| Primary Health Care | 13 | 2021 | 4839 | 1.09 | Why? |
| Antidepressive Agents | 3 | 2019 | 509 | 1.07 | Why? |
| Cardiovascular Agents | 2 | 2021 | 663 | 0.99 | Why? |
| Hypertension | 8 | 2019 | 8895 | 0.97 | Why? |
| Blood Glucose | 6 | 2018 | 3642 | 0.97 | Why? |
| Retrospective Studies | 58 | 2021 | 105322 | 0.96 | Why? |
| Drug Substitution | 4 | 2021 | 385 | 0.94 | Why? |
| Osteoporosis | 2 | 2018 | 410 | 0.94 | Why? |
| Serotonin Uptake Inhibitors | 3 | 2019 | 149 | 0.88 | Why? |
| Dipeptidyl Peptidase 4 | 2 | 2018 | 1061 | 0.85 | Why? |
| Gynecology | 3 | 2019 | 741 | 0.84 | Why? |
| Diuretics | 2 | 2019 | 326 | 0.83 | Why? |
| Stroke | 8 | 2019 | 8839 | 0.83 | Why? |
| Epistaxis | 2 | 2018 | 96 | 0.82 | Why? |
| Female | 92 | 2021 | 380317 | 0.81 | Why? |
| Rivastigmine | 1 | 2019 | 6 | 0.79 | Why? |
| Aged | 70 | 2021 | 215776 | 0.79 | Why? |
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2019 | 15 | 0.78 | Why? |
| Memantine | 1 | 2019 | 21 | 0.76 | Why? |
| International Classification of Diseases | 2 | 2019 | 265 | 0.76 | Why? |
| Middle Aged | 70 | 2021 | 270681 | 0.74 | Why? |
| Somatoform Disorders | 2 | 2019 | 153 | 0.74 | Why? |
| Sexually Transmitted Diseases, Bacterial | 1 | 2018 | 26 | 0.72 | Why? |
| Prevalence | 19 | 2021 | 25773 | 0.72 | Why? |
| Male | 77 | 2021 | 367725 | 0.72 | Why? |
| Sitagliptin Phosphate | 1 | 2018 | 82 | 0.72 | Why? |
| Pharmacoepidemiology | 1 | 2018 | 84 | 0.71 | Why? |
| Aged, 80 and over | 40 | 2021 | 88759 | 0.71 | Why? |
| Adamantane | 1 | 2018 | 68 | 0.71 | Why? |
| Valproic Acid | 1 | 2018 | 114 | 0.70 | Why? |
| Etanercept | 1 | 2019 | 162 | 0.70 | Why? |
| Insulins | 1 | 2017 | 26 | 0.70 | Why? |
| Labor Presentation | 1 | 2017 | 13 | 0.70 | Why? |
| Sick Leave | 1 | 2021 | 318 | 0.70 | Why? |
| Alzheimer Disease | 2 | 2019 | 1020 | 0.69 | Why? |
| Delirium | 2 | 2018 | 1061 | 0.69 | Why? |
| Aminobutyrates | 1 | 2019 | 142 | 0.69 | Why? |
| Dipeptides | 1 | 2018 | 106 | 0.69 | Why? |
| Prescription Drugs | 2 | 2020 | 243 | 0.69 | Why? |
| Tramadol | 1 | 2017 | 40 | 0.68 | Why? |
| Vestibular Diseases | 1 | 2018 | 68 | 0.68 | Why? |
| Contraceptives, Oral, Hormonal | 1 | 2017 | 42 | 0.66 | Why? |
| Patient Dropouts | 1 | 2017 | 96 | 0.66 | Why? |
| Thyroid Diseases | 2 | 2018 | 285 | 0.66 | Why? |
| Hepatitis A virus | 1 | 2017 | 68 | 0.66 | Why? |
| Fetal Distress | 1 | 2017 | 70 | 0.66 | Why? |
| Pregnancy, Ectopic | 1 | 2017 | 82 | 0.66 | Why? |
| Genital Diseases, Female | 1 | 2017 | 110 | 0.66 | Why? |
| Gout | 1 | 2018 | 85 | 0.65 | Why? |
| Acute Pain | 1 | 2017 | 73 | 0.64 | Why? |
| Cognitive Dysfunction | 2 | 2019 | 1389 | 0.64 | Why? |
| Hormone Replacement Therapy | 1 | 2018 | 146 | 0.64 | Why? |
| Tetrazoles | 1 | 2019 | 262 | 0.63 | Why? |
| Sexually Transmitted Diseases, Viral | 1 | 2018 | 115 | 0.63 | Why? |
| Encephalitis Viruses, Tick-Borne | 1 | 2017 | 100 | 0.62 | Why? |
| Thyrotropin | 1 | 2018 | 262 | 0.62 | Why? |
| Maternal Age | 1 | 2017 | 244 | 0.61 | Why? |
| Biosimilar Pharmaceuticals | 1 | 2019 | 205 | 0.61 | Why? |
| Thyroxine | 1 | 2018 | 250 | 0.61 | Why? |
| Thyroidectomy | 1 | 2018 | 207 | 0.61 | Why? |
| Encephalitis, Tick-Borne | 1 | 2017 | 86 | 0.60 | Why? |
| Depressive Disorder | 4 | 2021 | 1236 | 0.60 | Why? |
| Dizziness | 1 | 2018 | 275 | 0.60 | Why? |
| Neurologists | 1 | 2018 | 283 | 0.59 | Why? |
| Humans | 112 | 2021 | 930598 | 0.59 | Why? |
| Psychotropic Drugs | 2 | 2017 | 396 | 0.58 | Why? |
| Hypercholesterolemia | 1 | 2017 | 175 | 0.58 | Why? |
| Digestive System Neoplasms | 1 | 2017 | 146 | 0.58 | Why? |
| Sinusitis | 3 | 2019 | 649 | 0.58 | Why? |
| Abortion, Spontaneous | 2 | 2019 | 776 | 0.57 | Why? |
| Rhinitis | 2 | 2019 | 626 | 0.57 | Why? |
| Anticholesteremic Agents | 1 | 2017 | 186 | 0.56 | Why? |
| Arthritis | 1 | 2019 | 288 | 0.56 | Why? |
| Seasons | 2 | 2018 | 4071 | 0.56 | Why? |
| Infliximab | 1 | 2019 | 502 | 0.56 | Why? |
| Network Meta-Analysis | 1 | 2017 | 426 | 0.56 | Why? |
| Neoplasm Metastasis | 2 | 2018 | 682 | 0.55 | Why? |
| Secondary Prevention | 1 | 2019 | 762 | 0.55 | Why? |
| Psychiatry | 4 | 2019 | 1289 | 0.55 | Why? |
| Biological Products | 2 | 2019 | 2331 | 0.53 | Why? |
| Macular Degeneration | 1 | 2017 | 194 | 0.53 | Why? |
| Consumer Behavior | 1 | 2020 | 544 | 0.53 | Why? |
| Benzhydryl Compounds | 1 | 2017 | 240 | 0.52 | Why? |
| Analgesics | 1 | 2017 | 451 | 0.50 | Why? |
| Proportional Hazards Models | 7 | 2019 | 6543 | 0.50 | Why? |
| Multimorbidity | 1 | 2018 | 703 | 0.50 | Why? |
| Adult | 44 | 2021 | 244371 | 0.50 | Why? |
| Gynecologic Surgical Procedures | 1 | 2017 | 489 | 0.49 | Why? |
| Risk Factors | 24 | 2019 | 71621 | 0.49 | Why? |
| Case-Control Studies | 13 | 2019 | 17671 | 0.48 | Why? |
| Glucosides | 1 | 2017 | 359 | 0.48 | Why? |
| Insulin, Long-Acting | 1 | 2012 | 30 | 0.48 | Why? |
| Incidence | 13 | 2019 | 25622 | 0.47 | Why? |
| Chronic Disease | 5 | 2019 | 5139 | 0.47 | Why? |
| Glomerular Filtration Rate | 1 | 2018 | 1262 | 0.46 | Why? |
| Migraine Disorders | 1 | 2019 | 530 | 0.45 | Why? |
| Kaplan-Meier Estimate | 6 | 2019 | 4260 | 0.45 | Why? |
| Noncommunicable Diseases | 1 | 2021 | 934 | 0.44 | Why? |
| Fractures, Bone | 1 | 2017 | 487 | 0.43 | Why? |
| Alcoholism | 1 | 2018 | 691 | 0.43 | Why? |
| Osteoporotic Fractures | 3 | 2018 | 175 | 0.43 | Why? |
| Delayed Diagnosis | 1 | 2021 | 1529 | 0.43 | Why? |
| Body Weight | 1 | 2017 | 1074 | 0.42 | Why? |
| Mental Disorders | 3 | 2018 | 6742 | 0.42 | Why? |
| Mental Health Services | 2 | 2019 | 3007 | 0.41 | Why? |
| Atrial Fibrillation | 3 | 2019 | 2320 | 0.41 | Why? |
| Sexually Transmitted Diseases | 1 | 2018 | 694 | 0.41 | Why? |
| Patient Compliance | 1 | 2020 | 1468 | 0.41 | Why? |
| Genital Neoplasms, Female | 1 | 2017 | 718 | 0.40 | Why? |
| Metformin | 1 | 2017 | 640 | 0.40 | Why? |
| Hypoglycemia | 1 | 2015 | 406 | 0.40 | Why? |
| Parkinson Disease | 2 | 2019 | 1414 | 0.40 | Why? |
| Specialization | 3 | 2018 | 432 | 0.40 | Why? |
| Pain | 1 | 2017 | 1084 | 0.39 | Why? |
| Drug Utilization Review | 3 | 2019 | 72 | 0.38 | Why? |
| Anxiety | 5 | 2021 | 17311 | 0.37 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2019 | 2483 | 0.37 | Why? |
| Nootropic Agents | 2 | 2018 | 23 | 0.37 | Why? |
| Pregnancy Complications | 2 | 2017 | 1388 | 0.37 | Why? |
| Rheumatology | 1 | 2019 | 1213 | 0.36 | Why? |
| Angiotensin Receptor Antagonists | 3 | 2019 | 3892 | 0.36 | Why? |
| Frail Elderly | 1 | 2018 | 1427 | 0.36 | Why? |
| Survivors | 2 | 2019 | 2619 | 0.36 | Why? |
| Gastroenterology | 1 | 2019 | 1352 | 0.34 | Why? |
| Analgesics, Opioid | 1 | 2017 | 1070 | 0.34 | Why? |
| Delivery, Obstetric | 1 | 2017 | 1292 | 0.34 | Why? |
| Age Factors | 10 | 2019 | 21039 | 0.33 | Why? |
| Young Adult | 19 | 2021 | 93724 | 0.32 | Why? |
| Longitudinal Studies | 7 | 2019 | 9893 | 0.32 | Why? |
| Cesarean Section | 1 | 2017 | 2089 | 0.32 | Why? |
| Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.32 | Why? |
| Blood Pressure | 1 | 2018 | 2198 | 0.32 | Why? |
| Logistic Models | 6 | 2018 | 9089 | 0.31 | Why? |
| Orthopedics | 1 | 2017 | 1279 | 0.30 | Why? |
| Calcium Channel Blockers | 2 | 2019 | 367 | 0.30 | Why? |
| Anti-Bacterial Agents | 2 | 2018 | 10083 | 0.30 | Why? |
| Adrenergic beta-Antagonists | 2 | 2019 | 465 | 0.29 | Why? |
| Diabetes Complications | 1 | 2018 | 2358 | 0.29 | Why? |
| Drug Therapy, Combination | 4 | 2021 | 7268 | 0.29 | Why? |
| Time Factors | 11 | 2018 | 31397 | 0.29 | Why? |
| Urology | 1 | 2018 | 1685 | 0.29 | Why? |
| Risk | 4 | 2019 | 5288 | 0.29 | Why? |
| Disease Management | 3 | 2017 | 6841 | 0.28 | Why? |
| Workplace | 1 | 2017 | 2075 | 0.27 | Why? |
| Prostatic Neoplasms | 1 | 2017 | 1637 | 0.27 | Why? |
| Anxiety Disorders | 5 | 2021 | 2290 | 0.27 | Why? |
| Cardiovascular Diseases | 3 | 2020 | 11497 | 0.26 | Why? |
| Adolescent | 14 | 2021 | 86841 | 0.26 | Why? |
| Age Distribution | 3 | 2018 | 3567 | 0.26 | Why? |
| Follow-Up Studies | 6 | 2019 | 17020 | 0.26 | Why? |
| Pregnancy Outcome | 1 | 2017 | 3803 | 0.26 | Why? |
| Dermatology | 1 | 2019 | 1999 | 0.26 | Why? |
| United Kingdom | 6 | 2019 | 18046 | 0.26 | Why? |
| Occupational Stress | 1 | 2017 | 2044 | 0.25 | Why? |
| Cross-Sectional Studies | 10 | 2021 | 53120 | 0.24 | Why? |
| Recurrence | 3 | 2018 | 3675 | 0.24 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2017 | 1969 | 0.24 | Why? |
| Aging | 1 | 2018 | 3581 | 0.23 | Why? |
| Patient Acceptance of Health Care | 1 | 2021 | 5002 | 0.23 | Why? |
| Neoplasms | 3 | 2019 | 17251 | 0.23 | Why? |
| Physician Incentive Plans | 2 | 2018 | 18 | 0.23 | Why? |
| Otolaryngology | 4 | 2019 | 1917 | 0.22 | Why? |
| Anticoagulants | 2 | 2019 | 9563 | 0.21 | Why? |
| Sex Distribution | 2 | 2018 | 2083 | 0.21 | Why? |
| Nursing Homes | 4 | 2018 | 4155 | 0.21 | Why? |
| Kazakhstan | 1 | 2019 | 132 | 0.20 | Why? |
| Glucagon-Like Peptide-1 Receptor | 1 | 2021 | 138 | 0.20 | Why? |
| Delivery of Health Care | 3 | 2021 | 15909 | 0.19 | Why? |
| Chancroid | 1 | 2018 | 7 | 0.19 | Why? |
| Trichomonas Infections | 1 | 2018 | 24 | 0.19 | Why? |
| Healthcare Disparities | 1 | 2017 | 3893 | 0.19 | Why? |
| Odds Ratio | 4 | 2019 | 5861 | 0.19 | Why? |
| Drugs, Generic | 2 | 2018 | 136 | 0.19 | Why? |
| Lice Infestations | 1 | 2018 | 39 | 0.19 | Why? |
| Hemoglobinometry | 1 | 2017 | 6 | 0.19 | Why? |
| Pregnancy | 6 | 2019 | 23879 | 0.19 | Why? |
| Diabetes Mellitus | 2 | 2020 | 8207 | 0.18 | Why? |
| Condylomata Acuminata | 1 | 2018 | 62 | 0.18 | Why? |
| Panic | 1 | 2020 | 161 | 0.18 | Why? |
| Serotonin | 1 | 2019 | 137 | 0.18 | Why? |
| Vaccines | 1 | 2017 | 3692 | 0.18 | Why? |
| Neprilysin | 1 | 2019 | 112 | 0.18 | Why? |
| Cyclohexanecarboxylic Acids | 1 | 2017 | 15 | 0.18 | Why? |
| Herpes Genitalis | 1 | 2018 | 90 | 0.17 | Why? |
| Tamoxifen | 1 | 2018 | 83 | 0.17 | Why? |
| Valsartan | 1 | 2019 | 206 | 0.17 | Why? |
| Biphenyl Compounds | 1 | 2019 | 249 | 0.17 | Why? |
| Amines | 1 | 2017 | 67 | 0.17 | Why? |
| gamma-Aminobutyric Acid | 1 | 2017 | 52 | 0.17 | Why? |
| Heart Failure | 1 | 2019 | 6638 | 0.17 | Why? |
| Aromatase Inhibitors | 1 | 2017 | 45 | 0.17 | Why? |
| Prodromal Symptoms | 1 | 2018 | 133 | 0.17 | Why? |
| Homes for the Aged | 2 | 2017 | 1071 | 0.17 | Why? |
| Sex Factors | 3 | 2019 | 11014 | 0.17 | Why? |
| Insulin Glargine | 1 | 2017 | 43 | 0.16 | Why? |
| Drug Administration Routes | 1 | 2017 | 106 | 0.16 | Why? |
| Motivation | 2 | 2018 | 1640 | 0.16 | Why? |
| Treatment Outcome | 9 | 2019 | 51732 | 0.16 | Why? |
| Diphosphonates | 1 | 2017 | 121 | 0.16 | Why? |
| Angina Pectoris | 1 | 2017 | 114 | 0.16 | Why? |
| Cholinesterase Inhibitors | 1 | 2017 | 99 | 0.16 | Why? |
| Antidepressive Agents, Tricyclic | 1 | 2016 | 29 | 0.16 | Why? |
| Antineoplastic Agents, Hormonal | 1 | 2018 | 203 | 0.16 | Why? |
| Spondylitis, Ankylosing | 1 | 2019 | 231 | 0.16 | Why? |
| Multivariate Analysis | 2 | 2018 | 5440 | 0.15 | Why? |
| Nasal Polyps | 1 | 2019 | 221 | 0.15 | Why? |
| Neuroprotective Agents | 1 | 2019 | 240 | 0.15 | Why? |
| Endometriosis | 1 | 2017 | 130 | 0.15 | Why? |
| Anti-Arrhythmia Agents | 1 | 2018 | 325 | 0.15 | Why? |
| Chlamydia Infections | 1 | 2018 | 248 | 0.15 | Why? |
| Infertility | 1 | 2019 | 247 | 0.15 | Why? |
| Viral Vaccines | 1 | 2017 | 7560 | 0.15 | Why? |
| Salicylates | 1 | 2015 | 48 | 0.14 | Why? |
| Triazines | 1 | 2017 | 246 | 0.14 | Why? |
| Incidental Findings | 1 | 2019 | 487 | 0.14 | Why? |
| Risk Assessment | 6 | 2019 | 25439 | 0.14 | Why? |
| Lebanon | 1 | 2017 | 557 | 0.14 | Why? |
| Epidemiologic Methods | 1 | 2018 | 392 | 0.14 | Why? |
| Labor, Obstetric | 1 | 2017 | 257 | 0.14 | Why? |
| Gonorrhea | 1 | 2018 | 315 | 0.14 | Why? |
| Blood Pressure Determination | 1 | 2018 | 450 | 0.14 | Why? |
| Biological Therapy | 1 | 2019 | 456 | 0.13 | Why? |
| Syphilis | 1 | 2018 | 318 | 0.13 | Why? |
| Cardiologists | 1 | 2019 | 366 | 0.13 | Why? |
| Cholesterol, LDL | 1 | 2017 | 499 | 0.13 | Why? |
| Quarantine | 1 | 2021 | 18418 | 0.13 | Why? |
| Statistics, Nonparametric | 1 | 2017 | 1008 | 0.13 | Why? |
| Fasting | 1 | 2018 | 555 | 0.12 | Why? |
| Comorbidity | 4 | 2018 | 34796 | 0.12 | Why? |
| Cohort Studies | 5 | 2019 | 36005 | 0.12 | Why? |
| Arthritis, Psoriatic | 1 | 2019 | 625 | 0.12 | Why? |
| Abortion, Induced | 1 | 2019 | 437 | 0.12 | Why? |
| Patient Reported Outcome Measures | 1 | 2018 | 912 | 0.11 | Why? |
| Myocardial Infarction | 2 | 2018 | 3361 | 0.11 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.11 | Why? |
| Physicians | 3 | 2021 | 4214 | 0.11 | Why? |
| Demography | 1 | 2018 | 1660 | 0.11 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 5277 | 0.11 | Why? |
| Dyslipidemias | 1 | 2017 | 791 | 0.11 | Why? |
| Psychiatric Status Rating Scales | 1 | 2018 | 1340 | 0.11 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 1261 | 0.11 | Why? |
| Protective Factors | 1 | 2017 | 1720 | 0.11 | Why? |
| Poland | 1 | 2019 | 2368 | 0.11 | Why? |
| Health Services for the Aged | 1 | 2018 | 602 | 0.11 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.11 | Why? |
| Organizational Innovation | 1 | 2021 | 2468 | 0.11 | Why? |
| Ischemic Attack, Transient | 1 | 2015 | 439 | 0.10 | Why? |
| Data Mining | 1 | 2017 | 767 | 0.10 | Why? |
| Communicable Disease Control | 6 | 2021 | 29620 | 0.10 | Why? |
| Europe | 2 | 2017 | 12702 | 0.10 | Why? |
| Immunization Schedule | 1 | 2017 | 1305 | 0.10 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.10 | Why? |
| Risk Reduction Behavior | 1 | 2017 | 946 | 0.10 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.10 | Why? |
| Cognition | 1 | 2019 | 1394 | 0.10 | Why? |
| Regression Analysis | 1 | 2017 | 2484 | 0.10 | Why? |
| Self Care | 1 | 2018 | 918 | 0.10 | Why? |
| Drug Combinations | 1 | 2019 | 3852 | 0.09 | Why? |
| Seizures | 1 | 2017 | 1163 | 0.09 | Why? |
| Outpatients | 2 | 2021 | 3417 | 0.09 | Why? |
| Guideline Adherence | 2 | 2017 | 2309 | 0.08 | Why? |
| Electronic Health Records | 2 | 2017 | 3492 | 0.08 | Why? |
| Continuity of Patient Care | 1 | 2017 | 1574 | 0.08 | Why? |
| Monitoring, Physiologic | 1 | 2018 | 1956 | 0.08 | Why? |
| Sleep Wake Disorders | 1 | 2018 | 1463 | 0.08 | Why? |
| Neurology | 1 | 2018 | 1613 | 0.08 | Why? |
| Biomarkers | 3 | 2018 | 23361 | 0.08 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 1510 | 0.08 | Why? |
| Home Care Services | 1 | 2017 | 1351 | 0.07 | Why? |
| Referral and Consultation | 2 | 2019 | 4816 | 0.07 | Why? |
| Infant, Newborn | 2 | 2017 | 23105 | 0.07 | Why? |
| Arthritis, Rheumatoid | 1 | 2019 | 2043 | 0.07 | Why? |
| Child | 4 | 2018 | 70012 | 0.07 | Why? |
| Antiviral Agents | 1 | 2018 | 41703 | 0.07 | Why? |
| Body Mass Index | 1 | 2018 | 4306 | 0.07 | Why? |
| Clinical Decision-Making | 1 | 2018 | 3755 | 0.07 | Why? |
| Drug Costs | 2 | 2018 | 313 | 0.07 | Why? |
| Antirheumatic Agents | 1 | 2019 | 3023 | 0.07 | Why? |
| Patient Selection | 1 | 2018 | 4560 | 0.07 | Why? |
| Child, Preschool | 2 | 2017 | 36283 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.06 | Why? |
| Brain Ischemia | 1 | 2017 | 2813 | 0.06 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.06 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.06 | Why? |
| Ambulatory Care | 1 | 2019 | 4947 | 0.06 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.05 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.05 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.05 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.05 | Why? |
| Premenopause | 1 | 2018 | 63 | 0.05 | Why? |
| Postmenopause | 1 | 2018 | 160 | 0.04 | Why? |
| Pharmacovigilance | 1 | 2021 | 501 | 0.04 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.04 | Why? |
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 694 | 0.04 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2017 | 15421 | 0.04 | Why? |
| Vitamin K | 1 | 2017 | 263 | 0.04 | Why? |
| Chemotherapy, Adjuvant | 1 | 2018 | 606 | 0.04 | Why? |
| Budgets | 1 | 2017 | 155 | 0.04 | Why? |
| Infant | 1 | 2017 | 30274 | 0.03 | Why? |
| Prospective Studies | 1 | 2018 | 43301 | 0.03 | Why? |
| Coronavirus | 1 | 2021 | 18339 | 0.03 | Why? |
| Medicine | 1 | 2017 | 485 | 0.03 | Why? |
| Insurance, Health | 1 | 2016 | 634 | 0.03 | Why? |
| Observational Studies as Topic | 1 | 2017 | 1887 | 0.02 | Why? |
| Severity of Illness Index | 1 | 2017 | 48226 | 0.02 | Why? |
| Critical Pathways | 1 | 2019 | 1587 | 0.02 | Why? |
| World Health Organization | 1 | 2021 | 4213 | 0.02 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2017 | 1671 | 0.02 | Why? |
| Fibrinolytic Agents | 1 | 2017 | 1702 | 0.02 | Why? |
| Acute Disease | 1 | 2019 | 6029 | 0.02 | Why? |
| Thromboembolism | 1 | 2017 | 2101 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2018 | 3129 | 0.02 | Why? |
| Republic of Korea | 1 | 2017 | 5858 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.02 | Why? |
| Glucocorticoids | 1 | 2017 | 4431 | 0.01 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2021 | 27595 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |